Factors affecting the levels and pathways of atmospheric brominated flame retardant uptake by humans in different weather conditions

The health risks posed by atmospheric brominated flame retardants (BFRs) have been widely studied, but there remains a lack of clarity about exposure differences between clear days and haze days. We sampled the total suspended particle (TSP) and gaseous BFRs on clear days in summer, clear days in winter, and haze days in winter in Harbin, China, to investigate the variations in the concentrations and intakes (dermal and inhalation) in the different weather conditions. The concentrations of atmospheric BFRs were highest on haze days in winter (185 pg/m3), followed by clear days in summer (158 pg/m3), and clear days in winter (79.2 pg/m3), and these concentrations were significantly correlated with the concentrations of TSP. The human intake in the different weather conditions followed the pattern of the BFR concentrations, and the human intake of atmospheric BFRs was dominated by inhalation. A comparison of the BFR levels showed that the human intake of gaseous and particulate BFRs varied in the three weather conditions and that the inhalation intake, but not the dermal intake, was influenced under high concentrations of gaseous BFRs with low molecular weight

Occurrence and distribution of several endocrine-disrupting chemicals in a chemical park: exploring the health risks of multiple pollutants

Triclosan (TCS), triclocarban (TCC), parabens, bisphenols (BPAs), tetrabromobisphenol A and its alternatives (TBBPAs), and phthalate esters (PAEs) are typical endocrine-disrupting chemicals (EDCs), which have received increasing attention due to their potential adverse effects on ecological and human health. Human exposure to these EDCs is widespread. However, data regarding the distribution and related health risks of multiple EDCs in chemical parks are relatively scarce. In this study, 28 EDCs were determined in surface soil, sediment, and sludge samples collected from the Yangkou Chemical Industrial Park (Jiangsu, China). With the exception of TBBPAs, the distributions of Σ(TCS + TCC), Σ6parabens, Σ8BPAs, and Σ9PAEs in environmental media were as follows: sludge > sediment ≥ soil. No obvious differences were found regarding the concentrations of Σ9PAEs within the soil samples. Higher levels of Σ(TCS + TCC) (186 μg kg-1 dw) and Σ3TBBPAs (154 μg kg-1 dw) were found in the soil near a chemical manufacturer and the main sewage outlet of a wastewater treatment plant, respectively. The non-carcinogenic risks of EDCs from soil were estimated, and the risk levels were found to be a few orders of magnitude lower than the reported reference dose (RfD) values. The hazard indexes for all the samples were smaller than one, suggesting that the chemical industrial park posed a low risk to the workers. Additionally, the mass inventories of Σ(TCS + TCC), Σ6parabens, Σ8BPAs, Σ3TBBPAs, and Σ9PAEs were estimated to be 507, 90.6, 133, 20.7, and 1090 kg, respectively. These findings help to establish baseline concentrations for EDCs in soil, sediment, and sludge in a chemical industrial park

The effectiveness of the magnetic ring (LINX®) Device in managing reflux after sleeve gastrectomy; long term results: a seven-years’ experience

Aim: The magnetic ring (LINX®) system was approved by the FDA in 2012 as a device to augment the lower esophageal sphincter pressure to manage reflux in the general population. It was introduced into the bariatric population in 2014 as an alternative to Roux-en-Y gastric bypass (RYGB) in managing reflux after sleeve gastrectomy (SG).Materials: Between January 2015 and December 2021, Seventeen patients had the Magnetic Ring (MR) device placement to manage their reflux after SG.Methods: The mean age was 54 ± 12 years. Their mean body mass index (BMI) was 31 ± 6 kg/m2. The mean time between the SG and MR device placement was 41 ± 19 months. The mean DeMeester score was 48 ± 26 (normal < 14.72).Results: All seventeen patients underwent a successful laparoscopic placement of the MR device. Two patients had early post-operative dysphagia requiring removal of the device and one patient was lost to follow-up. The mean follow up of the remaining fourteen patients was 65 ± 31 months. Recurrent reflux occurred in 11 (79%). In three of these eleven (27%) patients the recurrent reflux was due to a broken device. None of these patients were interested in conversion to RYGB.Conclusion: The MR device is a valuable tool in treating reflux after SG in spite of its potential risk of recurrence. Our results can be interpreted as being dissatisfying if complete resolution is the goal. Larger studies, with more than 3 year follow up, are needed before a final decision is made on its value in the bariatric population

A novel insight into the nature of modified low-density lipoproteins and their role in atherosclerosis

Atherosclerosis plays a significant role in the development of cardiovascular diseases, the leading cause of death worldwide. Modification of low-density lipoproteins (LDLs) is a critical event in atherogenesis. Native LDL undergoes several modifications that can lead to the formation of atherogenic modified LDLs. LDL modifications change their physicochemical and biological properties. Possible modifications include changes in the lipoprotein particle’s structure, size, charge, and composition. Uptake and utilization of modified LDLs are impaired in cells. Macrophages take up modified LDLs that promote forming of foam cells, one of the critical cellular components of atherosclerotic lesions. Nevertheless, the direct role of each atherogenic LDL modification in atherogenesis remains uncertain. This review highlights LDL's most critical atherogenic modifications, including oxidized, enzyme-modified, non-oxidative, desialylated, glycated and carbamylated LDLs. Studying the role of each type of LDL modification will clarify the unknown elements of atherosclerosis progression and facilitate the development of effective methods for its diagnosis, treatment, and prevention

Recent advances in nonmetallic modulation of palladium-based electrocatalysts

Modulating the electrocatalytic performance of Palladium (Pd) with nonmetallic elements (e.g., H, B, C, N, O, P and S) has gained ever-increasing attention since their introduction has been proven to effectively modulate the 3d-electronic configuration and subsurface properties of Pd. In this review, the most advanced nonmetal-modified Pd-based catalysts are classified according to the different doped atoms (i.e., hydrides, borides, carbides, nitrides, oxides, phosphides and sulfides) and critically reviewed to emphasize the roles of nonmetallic elements doping on various electrocatalytic reactions. In each section, the synthetic strategies developed to incorporate nonmetals are discussed in detail. Furthermore, the optimized approaches of nonmetals-doped Pd-based catalysts and corresponding electrocatalytic enhancement mechanisms are also discussed clearly. Finally, the current challenges and future perspectives regarding nonmetal-modified Pd-based nanocatalysts are also outlined

Non-invasive prenatal diagnosis (NIPD): current and emerging technologies

Prenatal testing is important for the early detection and diagnosis of rare genetic conditions with life-changing implications for the patient and their family. Gaining access to the fetal genotype can be achieved using gold-standard invasive sampling methods, such as amniocentesis and chorionic villus sampling, but these carry a small risk of miscarriage. Non-invasive prenatal diagnosis (NIPD) for select rare monogenic conditions has been in clinical service in England since 2012 and has revolutionised the field of prenatal diagnostics by reducing the number of women undergoing invasive sampling procedures. Fetal-derived genomic material is present in a highly fragmented form amongst the maternal cell-free DNA (cfDNA) in circulation, with sequence coverage across the entire fetal genome. Cell-free fetal DNA (cffDNA) is the foundation for NIPD, and several technologies have been clinically implemented for the detection of paternally inherited and de novo pathogenic variants. Conversely, a low abundance of cffDNA within a high background of maternal cfDNA makes assigning maternally inherited variants to the fetal fraction a significantly more challenging task. Research is ongoing to expand available tests for maternal inheritance to include a broader range of monogenic conditions, as well as to uncover novel diagnostic avenues. This review covers the scope of technologies currently clinically available for NIPD of monogenic conditions and those still in the research pipeline towards implementation in the future

Recent progress of multilayer polymer electrolytes for lithium batteries

The significant market for electric vehicles and portable electronic devices is driving the development of high-energy-density solid-state lithium batteries. However, the solid electrolyte is still the main obstacle to the development of solid-state lithium batteries, mainly due to the lack of a single solid electrolyte that is compatible with both high-voltage cathodes and lithium metal anodes. These problems can potentially be solved with multilayer electrolytes. The property of each layer of the electrolyte can be tuned separately, which not only meets the different needs of the cathode and anode but also makes up for the shortcomings of each layer of the electrolyte, thereby achieving good mechanical properties and chemical and electrochemical stability. This review first presents a brief introduction to homogeneous single-layer electrolytes. The design principles of multilayer polymer electrolytes and the application of these principles using examples from recent work are then introduced. Finally, several suggestions as guides for future work are given

The change of paradigm in the treatment of HER2-positive breast cancer with the development of new generation antibody-drug conjugates

HER2-positive breast cancer is an aggressive disease. As a result of the development of specific HER2-targeted therapies, such as trastuzumab, more than 20 years ago, the prognosis of these patients has improved. Metastatic HER2-positive breast cancer patients are achieving better survival rates upon treatment with anti-HER2 therapies than patients with HER2-negative disease. Double HER2 blockade with trastuzumab and pertuzumab combined with a taxane achieved an unprecedented survival of over 57 months in first-line patients. Trastuzumab emtansine, the first antibody-drug conjugate approved for patients in second-line treatment was a potent cytotoxic agent bound to trastuzumab and is currently a standard therapeutic strategy. Despite the progress in treatment development, most patients develop resistance and eventually relapse. Advances in the design of antibody-drug conjugates have led to the development of new generation drugs with enhanced properties, such as trastuzumab deruxtecan and trastuzumab duocarmazine, which are significantly changing the paradigm in the treatment of HER2-positive metastatic breast cancer

Nano-TRAIL: a promising path to cancer therapy

Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand, also called apo-2 ligand (TRAIL/Apo-2L), is a cytokine that triggers apoptosis by binding to TRAIL-R1 (DR4) and TRAIL-R2 (DR5) death receptors. Apoptosis occurs through either the extrinsic or intrinsic pathway. The administration of recombinant human TRAIL (rhTRAIL) or TRAIL-receptor (TRAIL-R) agonists promotes apoptosis preferentially in cancerous cells over normal cells in vitro; this phenomenon has also been observed in clinical studies. The limited efficacy of rhTRAIL in clinical trials could be attributed to drug resistance, short half-life, targeted delivery issues, and off-target toxicities. Nanoparticles are excellent drug and gene delivery systems characterized by improved permeability and retention, increased stability and biocompatibility, and precision targeting. In this review, we discuss resistance mechanisms to TRAIL and methods to overcome TRAIL resistance by using nanoparticle-based formulations developed for the delivery of TRAIL peptides, TRAIL-R agonists, and TRAIL genes to cancer cells. We also discuss combinatorial approaches of chemotherapeutic drugs with TRAIL. These studies demonstrate TRAIL’s potential as an anticancer agent

Contrast-enhanced ultrasound for hepatocellular carcinoma detection and diagnosis in the context of nonalcoholic fatty liver disease

The prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing worldwide and is projected to become a major etiology of cirrhosis and hepatocellular carcinoma (HCC). HCC occurs more commonly in NAFLD patients who develop cirrhosis, though HCC is known to occur in the setting of noncirrhotic NAFLD as well. This is of particular importance given that the American College of Radiology (ACR) CT/MRI Liver Reporting and Data System (LI-RADS) algorithm may only be applied to a certain population of patients, and this population does not include those with noncirrhotic NAFLD. Conventional ultrasound (US) has long been in use for HCC surveillance, but contrast-enhanced US (CEUS) is a relatively newer modality, growing in use for assessment of liver lesions, and its use in HCC diagnosis has been formalized with CEUS LI-RADS. The use of US and CEUS in the assessment of liver lesions in NAFLD patients involves the consideration of certain particular nuances, and familiarity with these considerations will continue increasing in importance as the disease becomes more common